Open respiratory archives · 2026
The P4COPD Study: Rationale, Goals and Study Design - Prediction, Prevention, Personalized and Precision Management of COPD in Young Adults.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Agustí Àlvar, Carrizosa-Guerri Xènia, Casanova Ciro, Cosio Borja, Crispi Fatima, Fernández-Villar Alberto, Garcia-Aymerich Judith, González-de Paz Luis, Gonzalez Juan R, Iglesias Amanda, Izquierdo Jose Luis, Marin-Oto Marta, Marin Jose Maria, Novoa Rommy, Ocaña Andrea, Pascual Sergi, Peralta Gabriela, Perea Lídia, Sanz-Rubio David, Sarrat-Gonzalez David, Torrent Maties, Vazquez Miguel, Velasco Valle, Vila Marc, Faner Rosa, P4COPD Study Group
Аннотация
INTRODUCTION: Chronic obstructive pulmonary disease (COPD) is a major public health problem. Research over the past few years has shown that COPD is the result of dynamic and cumulative gene-environment interactions starting early in life. This opens new opportunities for the Prediction, Prevention, Personalized and Precise management (P4) of COPD in young adults. The P4COPD study sought to: (1) investigate the genomic and environmental/lifestyle determinants of COPD in young adults (18-50 years); (2) contrast them with those determined in children, adolescent and older individuals; and (3) explore the feasibility and cost of implementing a P4 strategy for COPD in young adults in clinical practice.
MATERIALS AND METHODS: The P4COPD study leverages from already existing cohorts (EarlyCOPD, INMA, LEVANTE, Aduheart) of young subjects (18-50 years) and de novo recruitment from primary care centers, in whom we: (1) analyzed demographic, epidemiological, clinical and physiologic information; (2) measured genetic, epigenetic and proteomic markers; (3) used analytical methods to identify endotypes, biomarkers and potential therapeutic targets associated with the presence of COPD, pre-COPD and/or low peak lung function. Results in young individuals: (4) were contrasted with healthy controls from the general population (IMPACT cohort) and COPD cohorts in older patients (BIOMEPOC, CHAIN and ECLIPSE). Besides, we (5) explored how to implement results in clinical practice; and (6) estimated its potential health cost implications.
RESULTS: First results are expected in the third and fourth quarters of 2026.
CONCLUSIONS: Identifying young individuals at risk of COPD, in whom to establish a P4 strategy is highly relevant to promote healthy aging.
MATERIALS AND METHODS: The P4COPD study leverages from already existing cohorts (EarlyCOPD, INMA, LEVANTE, Aduheart) of young subjects (18-50 years) and de novo recruitment from primary care centers, in whom we: (1) analyzed demographic, epidemiological, clinical and physiologic information; (2) measured genetic, epigenetic and proteomic markers; (3) used analytical methods to identify endotypes, biomarkers and potential therapeutic targets associated with the presence of COPD, pre-COPD and/or low peak lung function. Results in young individuals: (4) were contrasted with healthy controls from the general population (IMPACT cohort) and COPD cohorts in older patients (BIOMEPOC, CHAIN and ECLIPSE). Besides, we (5) explored how to implement results in clinical practice; and (6) estimated its potential health cost implications.
RESULTS: First results are expected in the third and fourth quarters of 2026.
CONCLUSIONS: Identifying young individuals at risk of COPD, in whom to establish a P4 strategy is highly relevant to promote healthy aging.